https://www.thebostonexaminer.com/article/912329227-best-mortgage-loan-officers-in-worcester-county-for-2026-and-why-ben-naranjo-leads-the-pack The Boston Examiner en PressRelease 2026-05-12T20:43:11+00:00 Best Mortgage Loan Officers in Worcester County for 2026 (And Why Ben Naranjo Leads the Pack) https://www.thebostonexaminer.com/article/912290566-enkrypt-ai-and-netapp-collaborate-to-bring-ai-risk-enforcement-to-the-data-layer The Boston Examiner en PressRelease 2026-05-12T17:40:53+00:00 Enkrypt AI and NetApp Collaborate to Bring AI Risk Enforcement to the Data Layer https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24854507-76-1920x1270.png https://www.thebostonexaminer.com/article/912235850-scroops-com-launches-ai-voice-rehearsal-platform-to-rebuild-social-skills The Boston Examiner en PressRelease 2026-05-12T16:00:00+00:00 Scroops.com Launches AI Voice Rehearsal Platform to Rebuild Social Skills https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24854154-scroops-com-hp-14-202605121256-2400x1350.png https://www.thebostonexaminer.com/article/912265559-gsk-global-ciso-warns-the-quantum-threat-to-enterprise-security-is-already-here The Boston Examiner en PressRelease 2026-05-12T15:52:21+00:00 GSK Global CISO Warns: The Quantum Threat to Enterprise Security Is Already Here https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24854350-michael-elmore-pr-1200x628.png https://www.thebostonexaminer.com/article/911332180-new-england-patriots-rb-treveyon-henderson-writes-foreword-for-gripped-part-6-the-dunkin-legacy The Boston Examiner en PressRelease 2026-05-12T14:30:00+00:00 New England Patriots RB TreVeyon Henderson Writes Foreword for 'Gripped Part 6: The Dunkin Legacy' https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24851053-treveyon-henderson-3035x2023.jpeg https://www.thebostonexaminer.com/article/912032393-contracts-365-launches-governed-ai-negotiation-companion-for-microsoft-365-enterprises The Boston Examiner en PressRelease 2026-05-12T14:15:00+00:00 Contracts 365 Launches Governed AI Negotiation Companion for Microsoft 365 Enterprises https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/23952032-contracts-365-black-logo-3860x540.jpeg https://www.thebostonexaminer.com/article/912227544-poseidon-s-forge-announces-sale-of-darkwake-auv-to-booz-allen-hamilton-to-accelerate-rapid-payload-integration The Boston Examiner en PressRelease 2026-05-12T14:00:00+00:00 Poseidon’s Forge Announces Sale of DarkWake AUV to Booz Allen Hamilton to Accelerate Rapid Payload Integration https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24854107-darkwake-on-beach-1800x1200.png https://www.thebostonexaminer.com/article/912241698-dr-karen-may-newman-to-receive-asaio-pushpa-and-kewal-gupta-lifetime-achievement-award The Boston Examiner en PressRelease 2026-05-12T13:31:02+00:00 Dr. Karen May-Newman to Receive ASAIO Pushpa and Kewal Gupta Lifetime Achievement Award https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24854190-asaio-2026-annual-conference-1050x300.jpeg https://www.thebostonexaminer.com/article/912240527-dr-gus-rosenberg-to-receive-asaio-kamal-and-narayan-bonde-lifetime-achievement-award-in-artificial-organs-development The Boston Examiner en PressRelease 2026-05-12T13:22:18+00:00 Dr. Gus Rosenberg to Receive ASAIO Kamal and Narayan Bonde Lifetime Achievement Award in Artificial Organs Development https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/23018408-asaio-logo-800x800.jpeg https://www.thebostonexaminer.com/article/911410109-engineer-brothers-launch-automata-studio-an-ai-native-software-and-marketing-agency The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 Engineer Brothers Launch Automata Studio, an AI-Native Software and Marketing Agency https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24851315-founders-1448x1086.png https://www.thebostonexaminer.com/article/911627983-authoronair-launches-ai-podcast-host-that-reads-your-book-before-the-interview The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 AuthorOnAir Launches AI Podcast Host That Reads Your Book Before the Interview https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24851818-authoronair-com-hp-13-202605091-2400x1350.png https://www.thebostonexaminer.com/article/912055087-abg-commercial-realty-facilitates-12-9-million-sale-of-westford-regency-inn-conference-center The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 ABG Commercial Realty Facilitates $12.9 Million Sale of Westford Regency Inn & Conference Center https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24853376-219-littleton-rd-1297x762.jpeg https://www.thebostonexaminer.com/article/911450497-easton-select-group-expands-north-shore-presence-with-acquisition-of-j-gallant-pool The Boston Examiner en PressRelease 2026-05-12T12:15:00+00:00 Easton Select Group Expands North Shore Presence with Acquisition of J. Gallant Pool https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24027682-easton-select-logo-1147x298.jpeg https://www.thebostonexaminer.com/article/911086522-bioventrix-names-carl-byrnes-chief-financial-officer The Boston Examiner en PressRelease 2026-05-12T10:30:00+00:00 BioVentrix® Names Carl Byrnes Chief Financial Officer https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24850114-carl-byrnes-1254x1254.jpeg https://www.thebostonexaminer.com/article/912327210-neumora-therapeutics-to-participate-in-2026-rbc-capital-markets-global-healthcare-conference The Boston Examiner en PressRelease 2026-05-12T20:05:00+00:00 Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference https://ml.globenewswire.com/media/48256578-6cd3-4332-bf9b-2f52cfa248b7/small/neumora-logo-jpg.jpg https://www.thebostonexaminer.com/article/912327213-fractyl-health-reports-first-quarter-2026-financial-results-and-business-updates The Boston Examiner en PressRelease 2026-05-12T20:05:00+00:00 Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates https://ml.globenewswire.com/media/3a379315-9c07-4655-883e-7e7f26c67778/small/fractyl-logo-png.png https://www.thebostonexaminer.com/article/912327333-atea-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update The Boston Examiner en PressRelease 2026-05-12T20:05:00+00:00 Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/1506ab30-7618-4ed0-98de-e3815adb3aa6/small/avir-png.png https://www.thebostonexaminer.com/article/912327452-damora-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights The Boston Examiner en PressRelease 2026-05-12T20:05:00+00:00 Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights https://ml.globenewswire.com/media/547722cf-495b-4464-97a9-35bea3fa5d15/small/damora-rgb-png.png https://www.thebostonexaminer.com/article/912327168-aura-biosciences-to-participate-in-upcoming-investor-conferences The Boston Examiner en PressRelease 2026-05-12T20:01:00+00:00 Aura Biosciences to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.thebostonexaminer.com/article/912327659-molecular-partners-reports-financial-results-and-highlights-for-q1-2026-with-clinical-studies-initiated-on-mp0712-and-mp0317 The Boston Examiner en PressRelease 2026-05-12T20:00:00+00:00 Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317 https://ml.globenewswire.com/media/ac0d728a-e43a-4d2b-a9c5-52e74d0dd1eb/small/molecularpartners-logo-jpg.jpg https://www.thebostonexaminer.com/article/912304554-ai-powered-crop-micronutrients-market-attracts-3-15-billion-in-investment-driven-by-precision-agriculture-revolution The Boston Examiner en PressRelease 2026-05-12T17:58:33+00:00 AI-Powered Crop Micronutrients Market Attracts $3.15 Billion in Investment, Driven by Precision Agriculture Revolution https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.thebostonexaminer.com/article/912304489-hubg-alert-hub-group-investigated-for-securities-fraud-investors-should-contact-block-leviton-to-potentially-recover-losses The Boston Examiner en PressRelease 2026-05-12T17:39:39+00:00 HUBG ALERT: Hub Group Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://www.thebostonexaminer.com/article/912262647-ahold-delhaize-usa-appoints-vipin-gopal-to-lead-data-and-ai The Boston Examiner en PressRelease 2026-05-12T14:00:00+00:00 Ahold Delhaize USA Appoints Vipin Gopal to Lead Data and AI https://ml.globenewswire.com/media/cab52a78-54be-4e34-a33f-a1c1da142938/medium/ahold-delhaize-usa-appoints-vipin-gopal-to-lead-data-and-ai.png https://www.thebostonexaminer.com/article/912262894-earned-signs-washington-nationals-prospect-miguel-sime-jr-as-brand-ambassador The Boston Examiner en PressRelease 2026-05-12T13:35:09+00:00 EARNED Signs Washington Nationals Prospect Miguel Sime Jr. as Brand Ambassador https://ml.globenewswire.com/media/70b36e31-d12f-4151-991e-2425ad8043fd/medium/earned-x-miguel-sime-jr.jpg https://www.thebostonexaminer.com/article/912244503-agios-submits-snda-to-fda-for-u-s-accelerated-approval-of-mitapivat-in-sickle-cell-disease The Boston Examiner en PressRelease 2026-05-12T13:31:00+00:00 Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png https://www.thebostonexaminer.com/article/912244021-beam-therapeutics-to-present-updated-biomarker-data-from-phase-1-2-beacon-trial-further-underscoring-risto-cel-s-ability-to-restore-red-blood-cell The Boston Examiner en PressRelease 2026-05-12T13:30:00+00:00 Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 https://ml.globenewswire.com/media/03af3276-c254-436a-b40d-2ad9a1025f95/small/beamlogo-color-cmyk-jpg.jpg https://www.thebostonexaminer.com/article/912244194-cogent-biosciences-announces-multiple-presentations-at-the-european-hematology-association-eha-2026-congress The Boston Examiner en PressRelease 2026-05-12T13:30:00+00:00 Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress https://ml.globenewswire.com/media/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e/small/cogent-biosciences-logo-rgb-png.png https://www.thebostonexaminer.com/article/912244306-disc-medicine-announces-multiple-presentations-across-portfolio-at-the-european-hematology-association-eha-2026-congress The Boston Examiner en PressRelease 2026-05-12T13:30:00+00:00 Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress https://ml.globenewswire.com/media/d212c899-9a87-4500-9382-573dfe9f12af/small/disc-logo-horiz-fullcolor-rgb-jpg.jpg https://www.thebostonexaminer.com/article/912244522-agios-to-present-new-data-at-eha-2026-reinforcing-the-significant-therapeutic-impact-of-mitapivat-across-multiple-rare-hemolytic-anemias The Boston Examiner en PressRelease 2026-05-12T13:30:00+00:00 Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png https://www.thebostonexaminer.com/article/912243707-rapid7-launches-cyber-governance-risk-and-compliance-grc-early-access-program-to-unify-security-data-risk-context-and-compliance-workflows The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 Rapid7 Launches Cyber Governance, Risk, and Compliance (GRC) Early Access Program to Unify Security Data, Risk Context, and Compliance Workflows https://ml.globenewswire.com/media/06ff63c6-b10c-4136-b7b8-ee70f03d0bfd/small/rapid7-logo.jpg https://www.thebostonexaminer.com/article/912243854-ai-adoption-accelerates-in-accounting-yet-fragmented-tools-keep-efficiency-just-out-of-reach-according-to-new-progress-software-report The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 AI Adoption Accelerates in Accounting, Yet Fragmented Tools Keep Efficiency Just Out of Reach, According to New Progress Software Report https://ml.globenewswire.com/media/2a4a917f-af24-458f-b64e-25e5e5cc6c26/small/progress-logo-jpg.jpg https://www.thebostonexaminer.com/article/912243967-tier-one-partners-named-to-provoke-media-s-2026-best-agencies-lists The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 Tier One Partners Named to PRovoke Media’s 2026 Best Agencies Lists https://ml.globenewswire.com/media/a0b4ce8b-6438-4ffc-8143-50ffb37674ce/small/tier-one-logo-jpg.jpg https://www.thebostonexaminer.com/article/912243983-mks-inc-declares-quarterly-cash-dividend The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 MKS Inc. Declares Quarterly Cash Dividend https://ml.globenewswire.com/media/a922cdbe-9964-4f52-86d5-ff5e42639bb0/small/mks-color-logo-jpg.jpg https://www.thebostonexaminer.com/article/912244012-71-of-organizations-suffered-at-least-one-identity-breach-in-the-past-year-sophos-research-finds The Boston Examiner en PressRelease 2026-05-12T13:00:00+00:00 71% of Organizations Suffered At Least One Identity Breach in the Past Year, Sophos Research Finds https://ml.globenewswire.com/media/35db908a-b7b8-4ce0-b920-69875da346ba/small/sophos-1200x628-png.png https://www.thebostonexaminer.com/article/912244802-fortis-life-sciences-awards-2026-abnano-vhh-discovery-grant-to-deliver-biosciences-for-targeted-drug-delivery-research The Boston Examiner en PressRelease 2026-05-12T12:40:00+00:00 Fortis Life Sciences Awards 2026 AbNano® VHH Discovery Grant to Deliver Biosciences for Targeted Drug Delivery Research https://ml.globenewswire.com/media/35b82fbc-92f2-41d4-abbb-3a83618a33b7/small/fortis-logo-purple-png.png https://www.thebostonexaminer.com/article/912244004-akari-therapeutics-secures-key-european-patent-for-its-novel-rna-splicing-modulator-adc-payload-strengthening-global-ip-estate-for-all-major-global The Boston Examiner en PressRelease 2026-05-12T12:33:00+00:00 Akari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global Markets https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://www.thebostonexaminer.com/article/912243944-byrna-technologies-sets-upcoming-investor-conference-schedule The Boston Examiner en PressRelease 2026-05-12T12:00:00+00:00 Byrna Technologies Sets Upcoming Investor Conference Schedule https://ml.globenewswire.com/media/b37ace10-a2b7-4002-8d20-1f4aff9c06c8/small/byrna-technologies-logo-jpg.jpg https://www.thebostonexaminer.com/article/912244299-corbus-pharmaceuticals-reports-q1-2026-financial-results-and-provides-a-corporate-update The Boston Examiner en PressRelease 2026-05-12T12:00:00+00:00 Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.thebostonexaminer.com/article/912244347-rhythm-pharmaceuticals-announces-new-data-presentations-at-the-2026-european-congress-of-endocrinology The Boston Examiner en PressRelease 2026-05-12T12:00:00+00:00 Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.thebostonexaminer.com/article/912244420-cerevance-completes-enrollment-in-pivotal-phase-3-parkinson-s-disease-trial-and-closes-oversubscribed-20-million-series-c-to-extend-runway-into-2027 The Boston Examiner en PressRelease 2026-05-12T12:00:00+00:00 Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 https://ml.globenewswire.com/media/7b8bba27-38bb-484c-afef-fc5a539ec4e5/small/cerevance-logo-px-jpg.jpg https://www.thebostonexaminer.com/article/912225796-collegium-completes-acquisition-of-azstarys-from-corium-therapeutics The Boston Examiner en PressRelease 2026-05-12T11:31:46+00:00 Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics https://ml.globenewswire.com/media/c9077b27-1a69-42a5-9f77-e39124f4d2a2/small/collegium-rgb-large-r-jpg.jpg https://www.thebostonexaminer.com/article/912225296-compass-therapeutics-to-participate-in-upcoming-may-investor-events The Boston Examiner en PressRelease 2026-05-12T11:30:00+00:00 Compass Therapeutics to Participate in Upcoming May Investor Events https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.thebostonexaminer.com/article/912225437-zevra-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-investor-conference The Boston Examiner en PressRelease 2026-05-12T11:30:00+00:00 Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference https://ml.globenewswire.com/media/cf39ab90-8c07-407d-a7ea-b7c9d48d44c4/small/zevra-inline-fullcolor-rgb-12in-300ppi-1-png.png https://www.thebostonexaminer.com/article/912225454-harvard-bioscience-announces-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-12T11:30:00+00:00 Harvard Bioscience Announces First Quarter 2026 Financial Results https://ml.globenewswire.com/media/6784a4a6-c259-489c-8b5b-05266f41b06f/small/hbio-logo-png.png https://www.thebostonexaminer.com/article/912225583-xilio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-pipeline-and-business-updates The Boston Examiner en PressRelease 2026-05-12T11:30:00+00:00 Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates https://ml.globenewswire.com/media/7e55cc25-f46f-423c-bf2a-e77ebaf69665/small/xilio-full-clr-logo-cmyk-png.png https://www.thebostonexaminer.com/article/912225294-sionna-therapeutics-reports-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 Sionna Therapeutics Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/0cda8c25-e758-4f0d-86f2-875df8411a9a/small/sionna-png.png https://www.thebostonexaminer.com/article/912225344-foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-in-may The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May https://ml.globenewswire.com/media/742c7e36-c026-4cb2-b89a-933512e66fea/small/foghorn-logo-color-jpg.jpg https://www.thebostonexaminer.com/article/912225346-arbor-biotechnologies-achieves-unprecedented-precise-in-vivo-reverse-transcriptase-editing-in-the-brain-using-a-single-aav-vector-opening-a-new-path The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases https://ml.globenewswire.com/media/68842426-d5ae-4dd2-800a-89d80ad4b3b7/small/arbor-biotech-logo-web-3-1-jpg.jpg https://www.thebostonexaminer.com/article/912225364-acumen-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-highlights The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/53dd23f0-4b5b-4b6b-9dfa-22b5db4c922b/small/picture1-png.png https://www.thebostonexaminer.com/article/912225403-seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.thebostonexaminer.com/article/912225577-c4-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights https://ml.globenewswire.com/media/50045422-c7cb-42b0-857a-1f69f1efc0a6/small/c4therapeutics-website-logo-fullcolor-r-png.png https://www.thebostonexaminer.com/article/912225749-climb-bio-to-present-at-upcoming-investor-conferences The Boston Examiner en PressRelease 2026-05-12T11:00:00+00:00 Climb Bio to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.thebostonexaminer.com/article/912027608-growthfactor-launches-first-mcp-integration-for-commercial-real-estate The Boston Examiner en PressRelease 2026-05-11T19:57:30+00:00 GrowthFactor Launches First MCP Integration for Commercial Real Estate https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24853229-growthfactor-mcp-claude-site-sc-1200x675.png https://www.thebostonexaminer.com/article/912030363-industry-leaders-gather-in-boston-for-the-2nd-annual-retrofit-usa-conference The Boston Examiner en PressRelease 2026-05-11T18:53:04+00:00 Industry Leaders Gather in Boston for the 2nd Annual Retrofit USA Conference https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24853246-retrofit-usa-1231x422.png https://www.thebostonexaminer.com/article/910584514-adam-geragosian-shares-insight-on-boston-s-split-spring-real-estate-market The Boston Examiner en PressRelease 2026-05-11T16:52:14+00:00 Adam Geragosian Shares Insight on Boston’s Split Spring Real Estate Market https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24853077-charlestown-1367x911.jpeg https://www.thebostonexaminer.com/article/911988174-tinyhood-and-parento-partner-to-redefine-the-parenting-experience-for-working-families The Boston Examiner en PressRelease 2026-05-11T16:32:50+00:00 Tinyhood and Parento Partner to Redefine the Parenting Experience for Working Families https://www.thebostonexaminer.com/article/911972701-electra-ai-following-bca-with-iron-horse-acquisition-ii-corp-nasdaq-irho-to-attend-xponential-2026-in-detroit The Boston Examiner en PressRelease 2026-05-11T15:37:43+00:00 ELECTRA AI, following BCA with Iron Horse Acquisition II Corp. (Nasdaq: IRHO), to attend XPONENTIAL 2026 in Detroit https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24852875-promotional-image-1273x912.png https://www.thebostonexaminer.com/article/911976800-folk-americana-roots-hall-of-fame-and-rhino-records-celebrate-the-50th-anniversary-of-legendary-grateful-dead-show The Boston Examiner en PressRelease 2026-05-11T14:11:59+00:00 Folk Americana Roots Hall of Fame and Rhino Records Celebrate the 50th Anniversary of Legendary Grateful Dead Show https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/18928474-farhof-logo-746x492.jpeg https://www.thebostonexaminer.com/article/910302750-north-attleboro-ma-mortgage-lender-releases-2026-home-loan-market-update-on-rates-and-buyer-activity The Boston Examiner en PressRelease 2026-05-11T13:00:00+00:00 North Attleboro, MA Mortgage Lender Releases 2026 Home Loan Market Update on Rates and Buyer Activity https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24847188-main-street-home-500x500.png https://www.thebostonexaminer.com/article/911874443-metalcon-launches-40-under-40-recognition-program The Boston Examiner en PressRelease 2026-05-11T13:00:00+00:00 METALCON Launches 40 Under 40 Recognition Program https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24852365-conference-header-512x60.png https://www.thebostonexaminer.com/article/911128575-adplus-beta-attracts-nearly-200-marketers-as-ai-ad-platform-sets-may-19-public-launch-date The Boston Examiner en PressRelease 2026-05-11T10:00:00+00:00 AdPlus Beta Attracts Nearly 200 Marketers as AI Ad Platform Sets May 19 Public Launch Date https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24850361-adplus-overview-hero-1200x628.jpeg https://www.thebostonexaminer.com/article/912055224-cargurus-to-present-at-the-j-p-morgan-2026-global-technology-media-and-communications-conference The Boston Examiner en PressRelease 2026-05-11T20:05:00+00:00 CarGurus to Present at the J.P. Morgan 2026 Global Technology, Media and Communications Conference https://ml.globenewswire.com/media/5e9ed825-143d-405a-9794-acd1a1ded2cc/small/cg-logo-2025-small-png.png https://www.thebostonexaminer.com/article/912055377-elicio-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-updates The Boston Examiner en PressRelease 2026-05-11T20:05:00+00:00 Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates https://ml.globenewswire.com/media/d588dddd-266e-4f3e-930a-d4c5ba15fe31/small/logo-jpg.jpg https://www.thebostonexaminer.com/article/912055613-amwell-to-participate-in-upcoming-investor-conference The Boston Examiner en PressRelease 2026-05-11T20:05:00+00:00 Amwell® to Participate in Upcoming Investor Conference https://ml.globenewswire.com/media/ff1989f5-0a6a-4e00-99dc-cb29a818aca5/small/amwell-logo-blue-2023-v02-rgb-2-png.png https://www.thebostonexaminer.com/article/912054692-aura-biosciences-reports-first-quarter-2026-financial-results-and-business-highlights The Boston Examiner en PressRelease 2026-05-11T20:01:00+00:00 Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.thebostonexaminer.com/article/912055156-aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026 The Boston Examiner en PressRelease 2026-05-11T20:01:00+00:00 Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://www.thebostonexaminer.com/article/912022499-ai-transforms-pharmaceutical-packaging-as-industry-invests-billions-in-zero-defect-quality-control-systems The Boston Examiner en PressRelease 2026-05-11T18:00:17+00:00 AI Transforms Pharmaceutical Packaging as Industry Invests Billions in Zero-Defect Quality Control Systems https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://www.thebostonexaminer.com/article/911981381-harvard-university-expands-multifaceted-research-alliance-with-northpond-labs-to-advance-solutions-in-healthcare The Boston Examiner en PressRelease 2026-05-11T14:00:00+00:00 Harvard University Expands Multifaceted Research Alliance with Northpond Labs to Advance Solutions in Healthcare https://ml.globenewswire.com/media/NGUxMzFjMzktMGVmMC00MTc5LWJhMWEtNTEwZjNiOTQxMDVhLTEyMjI2MTktMjAyNi0wNS0xMS1lbg==/tiny/Wyss-Institute-at-Harvard-Univ.png https://www.thebostonexaminer.com/article/911981486-lifeward-to-report-first-quarter-2026-financial-results-on-may-15-2026 The Boston Examiner en PressRelease 2026-05-11T13:25:58+00:00 Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026 https://ml.globenewswire.com/media/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007/small/lifeward-full-logo-rgb-for-web-01-jpg.jpg https://www.thebostonexaminer.com/article/911969945-the-boston-beer-company-lights-up-ready-to-drink-market-with-all-new-15-alc-lytt-electric-coolers The Boston Examiner en PressRelease 2026-05-11T13:15:00+00:00 The Boston Beer Company Lights Up Ready-To-Drink Market with All-New 15% Alc. LYTT® Electric Coolers™ https://ml.globenewswire.com/media/NDg2NmVkZjYtYmZmMi00OGJjLTliODQtNzljYWRmYWU1OGM4LTEyOTczMTgtMjAyNi0wNS0xMS1lbg==/tiny/Boston-Beer-Company.png https://www.thebostonexaminer.com/article/911970057-ernexa-therapeutics-releases-virtual-investor-kol-connect-segment-highlighting-ovarian-cancer-landscape-and-lead-candidate-erna-101 The Boston Examiner en PressRelease 2026-05-11T13:15:00+00:00 Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 https://ml.globenewswire.com/media/bb12f9ec-b7e7-4d8c-92df-cf27e238c398/small/ernexa-color-png.png https://www.thebostonexaminer.com/article/911970097-factorial-and-cartesian-iii-registration-statement-declared-effective-by-sec-in-connection-with-proposed-business-combination The Boston Examiner en PressRelease 2026-05-11T13:00:00+00:00 Factorial and Cartesian III Registration Statement Declared Effective by SEC in Connection with Proposed Business Combination https://ml.globenewswire.com/media/590fdd36-cafb-4be6-9468-4c69edcc0887/small/factorial-logo-black-1-png.png https://www.thebostonexaminer.com/article/911970294-electra-ai-and-iron-horse-acquisition-ii-corp-nasdaq-irho-release-additional-investor-materials The Boston Examiner en PressRelease 2026-05-11T13:00:00+00:00 ELECTRA AI and Iron Horse Acquisition II Corp. (Nasdaq: IRHO) Release Additional Investor Materials https://ml.globenewswire.com/media/ZGFkZjFjNmItMDAwMS00ZTBlLTlhZTMtMjQ2ZTA4ZmRhMTE4LTEzMjI5MjctMjAyNi0wNS0xMS1lbg==/tiny/Electra-AI.png https://www.thebostonexaminer.com/article/911970312-rocket-software-completes-acquisition-of-vertica-expanding-high-performance-analytics-and-ai-for-mission-critical-systems The Boston Examiner en PressRelease 2026-05-11T12:48:26+00:00 Rocket Software Completes Acquisition of Vertica, Expanding High-Performance Analytics and AI for Mission-Critical Systems https://ml.globenewswire.com/media/730dfd94-469c-4029-8d37-b3a2ddf5b762/small/rocket-software-logo-png.png https://www.thebostonexaminer.com/article/911969961-rapid7-to-participate-in-upcoming-investor-conferences The Boston Examiner en PressRelease 2026-05-11T12:30:00+00:00 Rapid7 to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/06ff63c6-b10c-4136-b7b8-ee70f03d0bfd/small/rapid7-logo.jpg https://www.thebostonexaminer.com/article/911970074-disc-medicine-to-participate-in-upcoming-investor-conferences The Boston Examiner en PressRelease 2026-05-11T12:30:00+00:00 Disc Medicine to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/d212c899-9a87-4500-9382-573dfe9f12af/small/disc-logo-horiz-fullcolor-rgb-jpg.jpg https://www.thebostonexaminer.com/article/911959972-sarm1-sir2501-fda-cipn The Boston Examiner en PressRelease 2026-05-11T12:13:40+00:00 维泰瑞隆SARM1抑制剂SIR2501获FDA快速通道资格，用于治疗化疗所致的周围神经病变（CIPN） https://ml.globenewswire.com/media/324eaac0-0f76-4b80-8917-0c56a174ae30/small/sironax-logo-768x768-png.png https://www.thebostonexaminer.com/article/911959975-sarm1-sir2501-fda-cipn The Boston Examiner en PressRelease 2026-05-11T12:13:40+00:00 維泰瑞隆SARM1抑制劑SIR2501獲FDA快速通道資格，用於治療化療所致的周圍神經病變（CIPN） https://ml.globenewswire.com/media/324eaac0-0f76-4b80-8917-0c56a174ae30/small/sironax-logo-768x768-png.png https://www.thebostonexaminer.com/article/907873239-brick-marketing-to-present-ai-search-seo-mastermind-sessions-at-smx-advanced-boston The Boston Examiner en PressRelease 2026-05-11T00:00:00+00:00 Brick Marketing to Present AI Search (SEO) Mastermind Sessions at SMX Advanced Boston https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24823393-brick-marketing-digital-marke-3402x2304.png https://www.thebostonexaminer.com/article/911959868-sironax-s-sarm1-inhibitor-sir2501-granted-fda-fast-track-designation-in-chemotherapy-induced-peripheral-neuropathy-cipn The Boston Examiner en PressRelease 2026-05-11T12:00:00+00:00 Sironax’s SARM1 Inhibitor SIR2501 Granted FDA Fast Track Designation in Chemotherapy-induced Peripheral Neuropathy (CIPN) https://ml.globenewswire.com/media/324eaac0-0f76-4b80-8917-0c56a174ae30/small/sironax-logo-768x768-png.png https://www.thebostonexaminer.com/article/911959489-intellia-therapeutics-announces-first-quarter-2026-financial-results-and-business-updates The Boston Examiner en PressRelease 2026-05-11T11:30:00+00:00 Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.thebostonexaminer.com/article/911959689-dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights The Boston Examiner en PressRelease 2026-05-11T11:30:00+00:00 Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights https://ml.globenewswire.com/media/2aa597a4-9b5c-4f0c-9ada-c5e06fa7d4de/small/dynelogo-r-final-full-color-rgb-jpg.jpg https://www.thebostonexaminer.com/article/911959841-bicara-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update The Boston Examiner en PressRelease 2026-05-11T11:30:00+00:00 Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://www.thebostonexaminer.com/article/911949353-apogee-therapeutics-provides-pipeline-progress-and-reports-first-quarter-2026-financial-results The Boston Examiner en PressRelease 2026-05-11T11:00:00+00:00 Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png https://www.thebostonexaminer.com/article/911949410-fractyl-health-authorized-to-initiate-first-in-human-trial-of-rjva-001-in-the-netherlands-first-gene-therapy-candidate-to-enter-clinical-development The Boston Examiner en PressRelease 2026-05-11T11:00:00+00:00 Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes https://ml.globenewswire.com/media/3a379315-9c07-4655-883e-7e7f26c67778/small/fractyl-logo-png.png https://www.thebostonexaminer.com/article/911949531-alpha-tau-announces-groundbreaking-interim-results-from-its-u-s-alpha-dart-recurrent-glioblastoma-trial-with-100-local-disease-control-67 The Boston Examiner en PressRelease 2026-05-11T11:00:00+00:00 Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg